Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: low-dose imaging Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Pain in Fibrous Dysplasia

NCT04125862
View directory record Official record
Conditions
Fibrous Dysplasia/McCune-Albright Syndrome
Interventions
MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NCT00706966
View directory record Official record
Conditions
Nonmalignant Neoplasm, Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

NCT02187627
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Volunteer
Interventions
[11C]RO6924963, [11C]RO6931643, [18F]RO6958948
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 23, 2026, 4:56 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

NCT06014385
View directory record Official record
Conditions
Muscarinic Receptor Occupancy
Interventions
Scopolamine, [11C]EMO ([11C]LSN3172176)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

NCT07284589
View directory record Official record
Conditions
Healthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors
Interventions
68Ga-Dotatate
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Completed No phase listed Observational

Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions

NCT01285440
View directory record Official record
Conditions
Suspicious Breast Lesion for Which Biopsy is Scheduled
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270
View directory record Official record
Conditions
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

NCT07084909
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
piflufolastat F 18
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

Adaptive Radiation for Abdominopelvic Metastases

NCT05880667
View directory record Official record
Conditions
Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Interventions
Adaptive Stereotactic Body Radiation
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

NCT00941070
View directory record Official record
Conditions
Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions
triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

NCT03882359
View directory record Official record
Conditions
Heart Diseases
Interventions
Echocardiogram, MVT-100, Definity
Diagnostic Test · Drug
Lead sponsor
Microvascular Therapeutics, LLC
Industry
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Kansas City, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Effects of Adolescent Synaptic Pruning

NCT07569718
View directory record Official record
Conditions
Healthy Adult Participants, Synaptic Plasticity
Interventions
PET Imaging Scan using [11C]UCB-J
Radiation
Lead sponsor
Beatriz Luna
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Recruiting Phase 3 Interventional

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

NCT07029217
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Radiation (Standard), Radiation (Very low dose)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EXPLORER PET/CT in Healthy Volunteers

NCT04110743
View directory record Official record
Conditions
Healthy
Interventions
EXPLORER PET/CT
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 23, 2026, 4:56 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 23, 2026, 4:56 PM EDT
Completed No phase listed Observational

NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer

NCT02103634
View directory record Official record
Conditions
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
Interventions
NaF PET/MRI, NaF PET/CT, FDG PET/CT
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 23, 2026, 4:56 PM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study

NCT02576067
View directory record Official record
Conditions
Vascular Inflammation, Atherosclerotic Cardiovascular Disease
Interventions
Low dose methotrexate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

NCT02775292
View directory record Official record
Conditions
Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Nivolumab, NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine, Positron Emission Tomography
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136
View directory record Official record
Conditions
No Evidence of Disease
Interventions
UV Light Therapy, Placebo, Celecoxib, Biopsy, Imaging Biomarker Analysis
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 23, 2026, 4:56 PM EDT
Terminated Phase 4 Interventional Results available

Inpatient Clinical Trial of NAC

NCT03581084
View directory record Official record
Conditions
Asthma
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

NCT01530997
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

NCT00671411
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer
Interventions
Ultrasound with intravenous microbubble contrast injection
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 23, 2026, 4:56 PM EDT